EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)

Abdullah AlSaleh iD, Mohammed Shahid, Eman Farid, Nermin Kamal, Khalid Bindayna

Access Microbiology · 03.02.2023 · 5 (2)

DOI: 10.1099/acmi.0.000475.v4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Access Microbiology, erschienen am 03.02.2023. Verfasst von Abdullah AlSaleh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availability and efficacy of therapy options. Recently, research has suggested that the remarkable antimicrobial effect of antioxidants against superbugs such as MRSA shows synergistic effects when accompanied by antimicrobial therapy. This paper aims to examine the synergistic effects of ascorbic acid and nicotinamide with a panel of antibiotics used in antimicrobial therapy against MRSA. Material and Methods. Two SCC mec type IV MRSA reference strains (EMRSA-15 and USA300) and 10 MRSA clinical isolates feature in this paper. SCC mec typing was conducted on the 10 clinical isolates via multiplex PCR after identification. Synergy experiments on antioxidants and antibiotics were evaluated via checkerboard assay. The minimum inhibitory concentration (MIC) of each agent was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) M100 guidelines through twofold microdilution assay. Results and Discussion. Synergy (FIC

Schlagwörter

Stichwörter der Autor:innen

MRSAantibiotic resistanceantioxidantsynergy

Autor:innen und Institutionen

  • Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.
  • AlSalmaniya Medical Complex, Microbiology Laboratory, Manama, Bahrain.

ORCID-Profile: Abdullah AlSaleh

Zitieren

APA

AlSaleh, A., Shahid, M., Farid, E., Kamal, N., & Bindayna, K. (2023). Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA). Access Microbiology, 5(2). https://doi.org/10.1099/acmi.0.000475.v4

Vancouver

AlSaleh A, Shahid M, Farid E, Kamal N, Bindayna K. Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA). Access Microbiology. 2023;5(2). doi:10.1099/acmi.0.000475.v4

BibTeX
@article{AlSaleh2023,
  author = {AlSaleh, Abdullah and Shahid, Mohammed and Farid, Eman and Kamal, Nermin and Bindayna, Khalid},
  title = {Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)},
  journal = {Access Microbiology},
  year = {2023},
  volume = {5},
  number = {2},
  doi = {10.1099/acmi.0.000475.v4}
}
Kostenlos starten →